Cargando…

A quantitative measure of treatment response in recent‐onset type 1 diabetes

INTRODUCTION: This paper develops a methodology and defines a measure that can be used to separate subjects that received an experimental therapy into those that benefitted from those that did not in recent‐onset type 1 diabetes. Benefit means a slowing (or arresting) the decline in beta‐cell functi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bundy, Brian N., Krischer, Jeffrey P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375065/ https://www.ncbi.nlm.nih.gov/pubmed/32704564 http://dx.doi.org/10.1002/edm2.143

Ejemplares similares

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
por: Jacobsen, Laura M., et al.
Publicado: (2020)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2010)

Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
por: Staeva, Teodora P., et al.
Publicado: (2013)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes
por: Wentworth, John M., et al.
Publicado: (2020)

Effect of Calcitriol on Bone Turnover and Osteocalcin in Recent-Onset Type 1 Diabetes
por: Napoli, Nicola, et al.
Publicado: (2013)

Verapamil and beta cell function in adults with recent-onset type 1 diabetes
por: Ovalle, Fernando, et al.
Publicado: (2018)

Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts
por: Zaharia, Oana P., et al.
Publicado: (2022)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

GABA and Combined GABA with GAD65-Alum Treatment Alters Th1 Cytokine Responses of PBMCs from Children with Recent-Onset Type 1 Diabetes
por: Heath, Katie E., et al.
Publicado: (2023)

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

Islet amyloid in recent-onset type 1 diabetes—the DiViD study
por: Westermark, Gunilla T., et al.
Publicado: (2017)

MAIT cell alterations in adults with recent-onset and long-term type 1 diabetes
por: Nel, Isabelle, et al.
Publicado: (2021)

The human gut microbiome in early-onset type 1 diabetes from the TEDDY study
por: Vatanen, Tommi, et al.
Publicado: (2018)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2014)

The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes
por: Bingley, Polly J., et al.
Publicado: (2015)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes
por: Cabrera, Susanne M., et al.
Publicado: (2018)

Vitamin D status and associated factors in recent-onset type 1 diabetic children in Iran
por: Ataie-Jafari, Asal, et al.
Publicado: (2012)

Evaluating T cell responses prior to the onset of type 1 diabetes
por: Arif, Sefina, et al.
Publicado: (2022)

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

Morphometric Changes in Lateral Ventricles of Patients with Recent-Onset Type 2 Diabetes Mellitus
por: Lee, Junghyun H., et al.
Publicado: (2013)

Long-Term Outcome of Individuals Treated With Oral Insulin: Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial
por: Vehik, Kendra, et al.
Publicado: (2011)

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data
por: Haller, Michael J., et al.
Publicado: (2019)

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial
por: Gitelman, Stephen E., et al.
Publicado: (2016)

An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
por: Cabrera-Rode, Eduardo, et al.
Publicado: (2022)

Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients
por: Casas, Rosaura, et al.
Publicado: (2020)

Type 1 Diabetes Risk Phenotypes Using Cluster Analysis
por: You, Lu, et al.
Publicado: (2023)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

A Rule-Based Prognostic Model for Type 1 Diabetes by Identifying and Synthesizing Baseline Profile Patterns
por: Lin, Ying, et al.
Publicado: (2014)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

The impact of hyperglycemia on urinary albumin excretion in recent onset diabetes mellitus type II
por: Nikolaidou, Barbara, et al.
Publicado: (2020)

C-Peptide Response and HLA Genotypes in Subjects With Recent-Onset Type 1 Diabetes After Immunotherapy With DiaPep277: An Exploratory Study
por: Buzzetti, Raffaella, et al.
Publicado: (2011)

At-Risk and Recent-Onset Type 1 Diabetic Subjects Have Increased Apoptosis in the CD4+CD25+(high) T-Cell Fraction
por: Glisic-Milosavljevic, Sanja, et al.
Publicado: (2007)

The Influence of Type 1 Diabetes Genetic Susceptibility Regions, Age, Sex, and Family History on the Progression From Multiple Autoantibodies to Type 1 Diabetes: A TEDDY Study Report
por: Krischer, Jeffrey P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qsgs3mgsieh2nj3ckce2d692ae